Drug
Pralsetinib
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Group | RET targeting TKI |
| Mechanism of Action | RET inhibitor |
| Half-life | 20 h (multiple dose); 16 h (single dose) |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
No direct radiosensitization data; theoretical reduction of RET-driven radioresistance only (Mulligan, New England Journal of Medicine, 2023; Duke et al., Clinical Cancer Research, 2023); though evidence is limited.
Data on this page refer exclusively to patients treated with
Pralsetinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
RET targeting TKI group page.